Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population.

Abstract

OBJECTIVE:

This study aimed to evaluate the effects of lorcaserin on body weight, cardiovascular risk factors, and safety in obese patients in Taiwan.

METHODS:

In this double-blind, randomised controlled trial, 171 obese adults were assigned to receive lorcaserin at a dose of 10mg, or placebo, twice a day for 24weeks. Diet and exercise counselling were given to all patients through the treatment period. Primary outcomes were proportion of patients achieving at least 5% and 10% reduction in body weight and mean change in body weight. Safety and tolerability endpoints such as Beck Depression Inventory-II, blood biochemistry, vital signs, and electrocardiogram were monitored.

RESULTS:

More patients receiving lorcaserin lost at least 5% body weight than receiving placebo (52.4% and 28.1%, P=0.001) with an average weight reduction of 5.8kg (95% CI: -6.91, -4.70) in lorcaserin group and those of 3.6kg (95% CI: -4.95, -2.33) in placebo group (P<0.05). The most common adverse effect with greater incidence in the lorcaserin group was self-limited dizziness. Serious adverse effect were rare and was reported by slightly more patients taking placebo than lorcaserin.

CONCLUSIONS:

In this multicentre, double-blinded placebo-controlled trial, lorcaserin was effective and well-tolerable in Asia group.

• Authors: Chia-Wen Lu, Chih-Jen Chang, Yi-Ching Yang, Wen-Yuan Lin, Kuo-Chin Huang
• Journal: Obesity research & clinical practice (Obes Res Clin Pract) Vol. 12 Issue 5 Pg. 465-471 (07 20 2018) ISSN: 1871-403X [Print] Netherlands
• PMID: 30033356 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2018 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.

Chemical References

• Anti-Obesity Agents
• Benzazepines
• lorcaserin

Topics

• Adult
• Anti-Obesity Agents (pharmacology, therapeutic use)
• Asian People
• Benzazepines (pharmacology, therapeutic use)
• Body Mass Index
• Cardiovascular Diseases
• Double-Blind Method
• Female
• Heart Rate (drug effects)
• Humans
• Male
• Middle Aged
• Obesity (drug therapy)
• Treatment Outcome
• Weight Loss (drug effects)
• Young Adult